Extended report
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:

    Dear Editor,

    Many thanks for the very interesting letter from Abud-Mendoza, highlighting their work in Mexico where they have successfully used rituximab in the treatment of both lupus nephritis and systemic lupus.
    Their initial report from 2006 [1] used rituximab as a treatment for refractory lupus nephritis and showed very detailed work on lymphocytes after rituximab administration. Supporting our data, th...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Are steroids required for therapy induction and relapses in lupus nephritis?
    • Carlos Abud-Mendoza, Proffesor
    • Other Contributors:
      • Carlos Abud-Mendoza, MD and Roberto Gonzalez Amaro MD

    Dear Editor,

    “A finger in the wound” is put by Condon et al. in their very interesting paper treating severe lupus nephritis with rituximab and mycophenolate, additionally to i.v. methyl-prednisolone, but not long-term oral steroids, achieving a good clinical response in most patients. 1

    Rheumatologists and nephrologists have the notion that glucocorticoids are the cornerstone for the treatment of autoimmune disea...

    Show More
    Conflict of Interest:
    None declared.